Live Breaking News & Updates on Pharmacia Corporation|Page 6

Stay updated with breaking news from Pharmacia corporation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial


Published: May 06, 2021
EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) Antares Pharma, Inc.. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests.
Mr. Renda has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals where he led a 200-person organization responsible for over $1B in annual sales and managed 5 unique therapeutic areas and institutional account teams. From 2012 to 2018, he held various positions of increasing responsibility at Novo Nordisk including Marketing Brand Director, Women’s Health Care and leading the commercial operations and effectiveness function responsible for a 150- ....

Josephv Renda , Patrick Shea , Women Health Care , Teva Pharmaceutical Industries Ltd , Company Annual Report On Form , Pfizer Inc , Idorsia Pharmaceuticals , Upjohn Company , Rare Disease At Mallinckrodt Pharmaceuticals , Us Sales Biopharmaceutical Division , Ferring Pharmaceuticals , Pennsylvania State University , Pharmacia Corporation , Exchange Commission , Corporate Communications , Antares Pharma , Idorsia Pharmaceuticals Ltd , Antares Pharma Inc , Novo Nordisk , Senior Vice President , Vice President , Rare Disease , Mallinckrodt Pharmaceuticals , Marketing Brand Director , Health Care , Biopharmaceutical Division ,

Antares Pharma Appoints Joseph Renda as Senior Vice


Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial
May 06, 2021 07:15 ET
| Source:
Antares Pharma, Inc.
Antares Pharma, Inc.
Ewing, New Jersey, UNITED STATES
EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests.
Mr. Renda has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals where he led a 200-person organization responsible for over $1B in annual sales and managed 5 unique therapeutic areas and institutional account teams. From 2012 to ....

Josephv Renda , Patrick Shea , Women Health Care , Teva Pharmaceutical Industries Ltd , Company Annual Report On Form , Pfizer Inc , Idorsia Pharmaceuticals , Upjohn Company , Rare Disease At Mallinckrodt Pharmaceuticals , Us Sales Biopharmaceutical Division , Ferring Pharmaceuticals , Pennsylvania State University , Pharmacia Corporation , Exchange Commission , Corporate Communications , Antares Pharma , Idorsia Pharmaceuticals Ltd , Antares Pharma Inc , Novo Nordisk , Senior Vice President , Vice President , Rare Disease , Mallinckrodt Pharmaceuticals , Marketing Brand Director , Health Care , Biopharmaceutical Division ,

Athersys Announces CEO Transition


Press release content from Business Wire. The AP news staff was not involved in its creation.
Athersys Announces CEO Transition
CLEVELAND, Ohio (BUSINESS WIRE) Feb 16, 2021
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Company’s President and Chief Operating Officer, as Interim Chief Executive Officer. Dr. Ismail Kola, Lead Director of the Athersys Board, has been appointed Chairman of the Board.
The Company’s Board is commencing a comprehensive search process to identify a permanent CEO. The Board intends to identify and select a CEO who can guide Athersys in the commercial stage. ....

University Of Chicago , United States , United Kingdom , University Of Cape Town , Western Cape , South Africa , Washington University , South Australia , Van Bokkelen , Gil Van Bokkelen , Williambj Lehmann , Goodrich Rosati , Ivor Macleod , John Harrington , Ondek Pty Ltd , Corporate Communications Investor Relations , Russo Partners , University Of South Africa , Human Disease At Monash Medical School , Cambridge University , Early Clinical Research Experimental Medicine At Schering , Plough Research Institute , Monash University Medical School , First Chicago Corporation , Rhodes University , Nuffield School Of Medicine ,

Detailed text transcripts for TV channel - CNN - 20100313:04:27:00

Risk of being convicted the shell company would take the hit. think of it as the great-great grandson of the parent company. birthday? march 27th, 2007. just in time to plead guilty in a kickback case against the company pfizer had acquired a few years earlier. with that conviction, pharmacia and upjohn company incorporated which had never sold so much as a single pill, was excluded from medicare. two years later when pfizer was in trouble with bextra, pharmacia and upjohn company incorporated, the shell company, stepped up again and pleaded guilty. it was like having an imaginary friend. an imaginary bad guy to take the rap. and pfizer, too big to nail, is still doing business with the federal government. it is true that if a company ....

Shell Company , Parent Company , March 27th , March 27th 2007 , Kickback Case , Upjohn Company Incorporated , Pharmacia Corporation , Imaginary Friend ,